Engel Law PLLC is investigating whether fair value to Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shareholders will result from the proposed acquisition of Zynerba by Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY) for (i) $1.1059 in cash, plus (ii) one non-tradable contingent value right per share (representing the right to receive potential additional payments of up to $140 million subject to the achievement of certain clinical, regulatory and sales milestones for Zygel — Zynerba’s lead new drug candidate) for each Zynerba share.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.